Trevi Therapeutics Announces Positive Outcome of the Sample Size Re-Estimation Analysis in PRISM Trial for Severe Pruritus in Patients With Prurigo NodularisGlobeNewsWire • 07/13/20
Trevi Therapeutics Announces Election of Dominick C. Colangelo to Board of DirectorsGlobeNewsWire • 06/30/20
Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Virtual ConferenceGlobeNewsWire • 06/17/20
Trevi Therapeutics to Participate in Panel Discussion at BTIG Pain / Pruritus Management ForumGlobeNewsWire • 09/05/19